Results 71 to 80 of about 96,658 (272)
New onset bronchial asthma following oral propranolol for infantile hemangioma
Respiratory Medicine Case ReportsPropranolol, a nonselective adrenergic beta-receptor blocker, is the first-line drug used for the treatment of infantile hemangiomas (IH). However, its use is contraindicated in patients with bronchial asthma.
Yuki Yamaguchi +4 more
doaj +1 more source
Treatment With Propranolol for Infantile Hemangioma in 13 Taiwanese Newborns and Young Infants
Pediatrics and Neonatology, 2012 Hemangioma in infants has a benign self-limited course, but the 10% of cases with complications need further treatment. Successful treatment with propranolol in western countries has been reported over the past few years.
Teng-Chin Hsu +6 more
doaj +1 more source
International Journal of Pediatrics, 2021 Purpose. Propranolol has been successful in treating problematic infantile hemangiomas (IH) but concerns regarding its effect on normal growth and development have been raised.
Rachel A. Giese +4 more
doaj +1 more source
Frontiers in Behavioral Neuroscience, 2016 Memory reconsolidation impairment using the β-noradrenergic receptor blocker propranolol is a promising novel treatment avenue for patients suffering from pathogenic memories, such as post-traumatic stress disorder (PTSD).
Hélène Villain +9 more
semanticscholar +1 more source
JCPP Advances, EarlyView.This systematic review investigated the association of prenatal exposure to antihypertensive medication with longer‐term poor neurodevelopmental outcomes by evaluating the findings from existing literature. We undertook a systematic review of previous studies looking specifically at neurodevelopmental outcomes in children.
Shrifah Alkhalaf +5 more
wiley +1 more source
Propranolol in the Treatment of Infantile Hemangiomas
Clinical, Cosmetic and Investigational Dermatology, 2021 Xin Tan, Shu Guo, Chenchao Wang Department of Plastic Surgery, First Hospital of China Medical University, Shenyang, Liaoning Province, People’s Republic of ChinaCorrespondence: Chenchao WangDepartment of Plastic Surgery, First Hospital of China Medical ...
Tan X, Guo S, Wang C
doaj
OncoTarget, 2016 In a previous study on a xenograft model of melanoma, we showed that the beta-adrenergic receptor antagonist propranolol inhibits melanoma development by modulating angiogenesis, proliferation and cell survival.
L. Wrobel +5 more
semanticscholar +1 more source
When protein losing enteropathy persists: A case series of viral and lymphatic‐associated etiologies
JPGN Reports, EarlyView.Abstract Protein‐losing enteropathy (PLE) is a rare condition that is characterized by loss of plasma protein in the intestines leading to hypoproteinemia with subsequent peripheral edema and possibly anasarca. The pathophysiology of PLE varies depending on the etiology and involves either intestinal mucosal injury or lymphatic system alterations ...
Natalie Jennings +7 more
wiley +1 more source
Propranolol induced G0/G1/S phase arrest and apoptosis in melanoma cells via AKT/MAPK pathway
OncoTarget, 2016 Both preclinical and epidemiology studies associate β-adrenoceptors-blockers (β-blockers) with activity against melanoma. However, the underlying mechanism is still unclear, especially in acral melanoma.
Chengfang Zhou +17 more
semanticscholar +1 more source
JEADV Clinical Practice, EarlyView.ABSTRACT Background Propranolol is widely adopted as the first‐line treatment for problematic infantile hemangioma (IH). Despite its efficacy and widespread use, concerns persist about potential long‐term neurodevelopmental risks, given propranolol′s ability to cross the blood‐brain barrier during early development. Objectives To evaluate the long‐term
Khalaf Kridin +3 more
wiley +1 more source